Bolt Projects Holdings, Inc.

Bolt Projects Holdings, Inc.

BSLKW
Bolt Projects Holdings, Inc.US flagOther OTC
0.01
USD
+0.00
- -
26,463.00Market Cap
Bolt Projects Holdings, Inc.
BSLKW
(Other OTC)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
3
1
3
Sales/Revenue/Turnover
-13,520.33
-15,332.08
-891.02
-3,030.44
-672.93
Operating Margin (%)
4
4
2
- -
- -
Depreciation Expense
-39
-52
-58
-65
-24
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-12,623.93
-14,942.49
-1,677.42
-4,762.78
-774.2
Profit Margin (%)
55
21
-23
2
-3
Working Capital
25
51
15
13
13
LT Debt
-268
-318
-113
-9
-13
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
13
13
13
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
4
Market Capitalization
- -
- -
- -

Working Capital

FRC

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
5
3
7
Cash, Cash Equivalents & STI
1
1
5
Accounts Receivable, Net
1
1
- -
Inventories
2
- -
1
Total Current Liabilities
7
9
11
Payables & Accruals
7
9
11
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-92.35%
Free Cash Flow
- -
- -
-46.43%
Net Income, GAAP
- -
- -
13.29%
Sales/Revenue/Turnover
- -
- -
-60.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1
1
- -
- -
3
2024
- -
- -
- -
1
1
2025
- -
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Bolt Projects Holdings, Inc. (Nasdaq: BSLKW) develops and produces innovative biomaterials for the beauty and personal care industry, leveraging biotechnology platforms inspired by nature to create sustainable alternatives to petroleum-based polymers and silicone elastomers. The company offers flagship products from its Vegan Silk Technology Platform, including b-silk, a fully biodegradable, non-toxic, vegan protein polymer used in haircare, skincare, and color cosmetics; and xl-silk, a silicone replacement for high-performance formulations; both manufactured at scale using renewable inputs such as yeast, water, sugar, and salt. Founded in 2009 and headquartered in San Francisco, California, Bolt Projects Holdings operates primarily in the United States, targeting global beauty brands seeking efficacious, environmentally friendly ingredients with an intellectual property portfolio comprising 62 granted patents and 173 pending applications. In recent developments, the company completed a business combination with Golden Arrow Merger Corp in August 2024, transitioning Bolt Threads into the publicly traded Bolt Projects Holdings, Inc. and listing its common stock and warrants on Nasdaq under BSLK and BSLKW, respectively, supported by PIPE investments from investors including Baillie Gifford, Temasek, and Founders Fund. In September 2025, Bolt secured a $20 million equity purchase agreement with Ascent Partners Fund LLC to fund working capital and general corporate purposes. Additional customer launches incorporating b-silk are underway, including haircare extensions with Vegamour since 2020 and anticipated color cosmetics debuts in early 2025, driving revenue growth to $3.4 million in 2023 and positioning the company to capitalize on regulatory shifts away from silicones.